(Hypertension. 1999;34:969-975.)
© 1999 American Heart Association, Inc.
Scientific Contributions |
AT1 Receptor Antagonism Reduces Endothelial Dysfunction and Intimal Thickening in Atherosclerotic Rabbits
From Novartis Pharma (M.D., J.M.), Basle, Switzerland; Unidad de Hipertensión, Hospital 12 de Octubre (L.M.R.), Madrid, Spain; Departamento de Fisiología, Facultad de Medicina, Universidad Complutense (N.d.l.H., R.M., S.V.-P., J.N.-C., V.C., V.L.), Madrid, Spain; and Servicio de Anatomía Patológica, Unidad II, Hospital Universitario de San Carlos (P.A.), Madrid, Spain.
Correspondence to V. Lahera, Departamento de Fisiología, Facultad de Medicina, Universidad Complutense, Madrid 28040, Spain. E-mail htnren{at}eucmax.sim.ucm.es
Abstract—The effects of angiotensin (AT)1 receptor antagonists on functional and morphological alterations associated with atherosclerosis are not well known. The current study was performed to examine the long-term effects of valsartan (3 or 10 mg/kg per day for 10 weeks) on endothelial function and structural changes in aorta from rabbits fed with either a control diet or a cholesterol-enriched diet. Rabbits fed with the cholesterol-rich diet showed higher (P<0.05) plasma levels of cholesterol than did controls. Treatment with valsartan (3 or 10 mg/kg per day) did not alter plasma cholesterol levels or systolic arterial pressure in any group. Contractions induced by angiotensin II were comparable in both control and hypercholesterolemic rabbits and were markedly reduced by treatment with valsartan. Relaxations induced by acetylcholine were lower in hypercholesterolemic rabbits than in controls. Treatment with valsartan (3 or 10 mg/kg per day) enhanced (P<0.05) this response in hypercholesterolemic rabbits but not in controls. Lumen and media cross-sectional areas were comparable in control and hypercholesterolemic rabbits. Vessel area was higher (P<0.05) in hypercholesterolemic rabbits than in controls. Intimal lesion was 29.5±6% in cholesterol-fed rabbits and nonexistent in control rabbits. Treatments with 3 and 10 mg/kg per day valsartan reduced (P<0.05) intimal lesion to 2.4±0.7% and 2.7±0.9%, respectively, and increased lumen area in hypercholesterolemic rabbits. No changes in either vessel or media cross-sectional areas were observed in these animals. In summary, angiotensin II, through AT1 receptors, appears to play a key role in the development of the vascular functional and structural changes associated with hypercholesterolemia. AT1 receptor antagonists, besides their antihypertensive effects, could be an important therapeutic tool to reduce the development of atherosclerosis.
Key Words: angiotensin II • receptors, angiotensin II • atherosclerosis • hypercholesterolemia • endothelium
This article has been cited by other articles:
 |
|
 |
|
  N. de las Heras, M. Ruiz-Ortega, M. Ruperez, D. Sanz-Rosa, M. Miana, P. Aragoncillo, S. Mezzano, V. Lahera, J. Egido, and V. Cachofeiro Role of connective tissue growth factor in vascular and renal damage associated with hypertension in rats. Interactions with angiotensin II Journal of Renin-Angiotensin-Aldosterone System, December 1, 2006; 7(4): 192 - 200. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Sola, M. Q.S. Mir, F. A. Cheema, N. Khan-Merchant, R. G. Menon, S. Parthasarathy, and B. V. Khan Irbesartan and Lipoic Acid Improve Endothelial Function and Reduce Markers of Inflammation in the Metabolic Syndrome: Results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) Study Circulation, January 25, 2005; 111(3): 343 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Johnstone, A. S. Perez, I. Nasser, R. Stewart, A. Vaidya, F. Al Ammary, B. Schmidt, G. Horowitz, J. Dolgoff, J. Hamilton, et al. Angiotensin Receptor Blockade With Candesartan Attenuates Atherosclerosis, Plaque Disruption, and Macrophage Accumulation Within the Plaque in a Rabbit Model Circulation, October 5, 2004; 110(14): 2060 - 2065. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Miyakawa, M. de Lourdes Junqueira, and J. E. Krieger Identification of two novel shear stress responsive elements in rat angiotensin I converting enzyme promoter Physiol Genomics, April 13, 2004; 17(2): 107 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Cediel, D. Sanz-Rosa, M. P. Oubina, N. de las Heras, F. R. G. Pacheco, O. Vegazo, J. Jimenez, V. Cachofeiro, and V. Lahera Effect of AT1 receptor blockade on hepatic redox status in SHR: possible relevance for endothelial function? Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2003; 285(3): R674 - R681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Brasier, A. Recinos III, and M. S. Eledrisi Vascular Inflammation and the Renin-Angiotensin System Arterioscler. Thromb. Vasc. Biol., August 1, 2002; 22(8): 1257 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.O. Lim and T.M. MacDonald Step test in hypertension QJM, November 1, 2000; 93(11): 703 - 705. [Full Text] [PDF]
|
|
|
|
|
|
M. d. Gasparo, P. Hess, B. Nuesslein-Hildesheim, P. Bruneval, and J.-P. Clozel Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction Journal of Renin-Angiotensin-Aldosterone System, June 1, 2000; 1(2): 151 - 158. [Abstract] [PDF]
|
|
|
|
|
|
M. de Gasparo New basic science initiatives with the angiotensin II receptor blocker valsartan Journal of Renin-Angiotensin-Aldosterone System, June 1, 2000; 1(2_suppl): S3 - S5. [Abstract] [PDF]
|
|
|
|
|
|
J. M Neutel Hypertension and its management: a problem in need of new treatment strategies Journal of Renin-Angiotensin-Aldosterone System, June 1, 2000; 1(2_suppl): S10 - S13. [Abstract] [PDF]
|
|